Pharmaceutical corporations and governments have been too quiet about COVID-19 therapies. That is the opinion of former Statistician-Normal, Pali Lehohla. He is questioning why therapies like Ivermectin, hydroxychloroquine, and South Africa’s optic bronchoscopy are being largely ignored. Lehohla believes these improvements are seen as a menace to earnings. Courtesy #DStv403
View at DailyMotion
